




Issue 1 July 2017



#### In this Issue

- Welcome message from the president of ACACR \*
- The ACACR inaugural meeting \*
- Member research highlights \*
- Member achievements \*
- \* Job openings
- \* How to become a member

# Welcome message from the president of ACACR



### Editor-in-Chief

Erxi Wu

Editors Research Highlights Zhenghe John Wang

Advertisements Nancy Du

Web Publishing Wenwei Hu

Issue editor Zhenghe John Wang

Contact acacrnews@gmail.com

#### Dear Colleagues and Friends,

At the 108th annual meeting of American Association for Cancer Research (AACR) in Washington DC, we proudly announced the establishment of our organization, Association of Chinese American on Cancer Research (ACACR) with approximately 200 attendees on April 3, 2017. Currently, we have a total of 688 colleagues and friends in our two WeChat groups. We are professors, researchers, medical doctors and professionals in pharmaceutical industries and health-related agencies who study or work on medical issues related to cancers. Although we are working and living in different countries, including United States of America, China, Asia, Europe and other regions, in the world, we have come together with our common goals to promote intellectual interactions and scientific collaborations and to bridge basic cancer research with translational research and to expedite pharmaceutical drug discovery/development for innovative and personalized medicine/oncology for cancer prevention, prognosis and treatments. To make our efforts more significant and broader, we will also work with the established national and international organizations, such as AACR, ACS, and other agencies, not only to advance our aforementioned common goals, but also to promote our active participations in the cancer community activities and programs organized by these organizations. In addition, we will work together with our sister organizations, such as US Chinese Anti-Cancer Association (USCACA) and Chinese American Hematologist and Oncologist Network (CAHON), with our own focuses and goals to promote international and national collaborations in disseminating cancer research and strengthening clinical improvement for cancer treatments in the world.

Fighting cancer, making cancer history, and helping patients and cancer survivors are our ultimate goals and missions. Together, we will stand out for cancer patients and survivors, and actively participate in all of the activities and programs in our association as well as in other organizations. Looking forward to our fruitful interactions, collaborations and participations in cancer research in the coming year.

Sincerely yours,

Shi-Yuan Cheng

## The ACACR inaugural Meeting



The Association of Chinese Americans in Cancer Research (ACACR) held its inaugural meeting in Capital Hilton hotel in Washington DC on April 2, 2017. The meeting was chaired by **Dr. Shi-Yuan Cheng**, president of ACACR and professor from Northwestern University, **Dr. Zhenkun Lou**, president-elected and professor from Mayo Clinic, **Dr. Shuli Xia**, general secretary of ACACR and professor from John Hopkins University and **Drs. Tongchuan He** (chair), **Peter Zhou and Gloria Su** (co-chairs) of the annual meeting committee. The meeting was well attended by over 250 Chinese cancer researchers from different institutions/universities in US and world-wide.

**Dr. Xia** kicked off the meeting by announcing the birth of ACACR. **Dr. Cheng** then introduced the mission of ACACR as "to prevent and cure cancer through promoting research among Chinese Americans in all areas of cancer including cancer biology, etiology, genetics, epidemiology, prevention, diagnosis, and treatment; to foster interactions and collaborations among professionals of Chinese background and/or ethnicity in cancer research through the exchange of information in education, technology, employment, and business opportunities; to promote interactions with other professional organizations in the field of cancer research". The main goal of ACACR is to become the major organization that represents all of the Chinese Americans in cancer research, and to provide a platform in which mutual helps and information can be exchanged freely.

The ACACR public committee chair, **Dr. Lin Zhang**, professor from University of Pittsburgh, outlined the plan of promoting the participation of Chinese scientists in various activities of AACR. First, the ACACR leadership will communicate with AACR president (including current, elected and future candidates), inform AACR the status and activities of ACACR members, and serves as a liaison of AACR president and cancer organizations and government funding agencies in China. ACACR also plans to establish potential SU2C-China (US-China dream team) funding mechanism to boost cancer research in China and Asian countries. Second, ACACR leadership will identify and recommend members who are qualified to serve in AACR program committees and subcommittees in AACR annual meeting as well as AACR special conferences. Third, the ACACR leadership will recommend members who are qualified to serve in equalified to serve in editorial boards, managing and/senior editors of the AACR journals.

**Dr. Jianmin Fang**, professor from Tongji University in China, delivered a key-note lecture on Chondrocyte differentiation from stem cells, followed by **Ms. TingMei Chau** from the Budget Office at U.S. Department of Health and Human Services, who provided insights to the federal budget process and NIH budget on biomedical and cancer research for the coming years. Drs. **Qingyi Wei** and **Wei Zhang**, founders of US Chinese Anti-Cancer Association (USCACA), also attended this meeting and expressed their warm congratulations to the inauguration of ACACR.

Looking forward, President-elected **Dr. Lou** declared that "Cancer research cannot depend on individual effort, it takes a whole village, in particular, it requires all the efforts and participation from Chinese scientists and cancer researchers."

The meeting was sponsored by Tanon and Novoproein.



# Member Achievement/Award

## Zhenghe John Wang won SU2C Colorectal Cancer Dream Team grant Award

ACACR member, Zhenghe John Wang, was named as co-leader of the Stand Up To Cancer (SU2C) Colorectal Cancer Dream Team, with funding of \$12 million from SU2C. John Wang is professor and vice chair of Department of Genetics and Genome Science at Case Western Reserve University, a coleader of cancer Genetics program of Case Comprehensive Cancer center. This grant will support a phase II clinical trial of targeting glutamine metabolism in patients whose tumors harbor PIK3CA mutation, stemmed from novel discoveries made by his laboratory.



Left to right, AACR CEO Margaret Foti, PhD; SU2C President Sung Poblete, RN, PhD; SU2C Colorectal Cancer Dream Team Co-Leaders Charles S. Fuchs, MD, MPH, and Lewis Cantley, PhD; Team Leader Luis A. Diaz, MD; SU2C Co-Founder Katie Couric; Dream Team Co-Leader Zhenghe Wang, PhD; Dream Team Principal Ryan B.Corcoran, MD, PhD; SU2C researcher Kurt Schalper, MD, PhD from Yale Cancer Center; and SU2C Co-Founder Kathleen Lobb at the Colorectal Cancer Dream Team announcement on Monday, April 3, 2017 at American Association for Cancer Research Annual Meeting 2017 in Washington, DC. (Paul Morigi/AP Images for Stand Up To Cancer)



# RESEARCH HIGHLIGHTS

Haian Fu at Emory University delineates a comprehensive protein-protein interaction networks in lung cancer. <u>http://www.nature.com/articles/ncomms14356</u>

**Hua Lu** at Tulane University recently published a series of studies that provide novel insights to p53 tumor suppressor functions: (1) PHLDB3 supports cancer growth via p53-mediated negative feedback; <u>http://www.nature.com/articles/ncomms13755</u> (2) a new p53 target miRNA miR-139-5p that can suppress the expression and activity of oncogenic cAMP specific phosphodiesterase 4D;

https://www.ncbi.nlm.nih.gov/pubmed/27383270 and (3) p53-MDM2 and p53-MDMX feedback loops paly a role in endocrine pancreatic development. https://www.ncbi.nlm.nih.gov/pubmed/28118981

**Chenkun LOU** at Mayo Clinic identified a CDK4/6dependent activation of DUB3 regulates cancer metastasis through SNAIL1/. <u>http://www.nature.com/articles/ncomms13923</u>

**Peter (Binhua) Zhou** at University of Kentucky also independently identified a similar mechanism. https://www.nature.com/articles/ncomms14228

Shuli Xia at Johns Hopkins University uncovered a novel transcriptional regulation mechanism that Kr ü ppel-like factor 4 (KLF4)mediated DNA methylation-dependent gene activation. https://elifesciences.org/articles/20068

**Zhaohui Wu** at University of Tennessee Health Science Center identified two microRNAs, miR-181 and miR-621, involve in therapeutic resistance of cancer cells.

ttps://www.nature.com/onc/journal/v35/n10/full/onc2015189a.html https://www.nature.com/onc/journal/v35/n4/full/onc201596a.html

Research highlight is a benefit provided to ACACR members only. Please see the next page for instructions of how to become a member of ACACR.

# How to become a member of ACACR 如何成为ACACR 协会会员

You are invited

感谢大家对ACACR 的关心和鼓励,更感谢许多志愿者们的付出。我们的财务 李勇已把协会的银行帐户, PayPal 帐户开好;我们 IT 小组的戴木水已经将网上自动付 款体系建成;我们会员小组的席亚光已将会员注册的表格等设计好。下面是如何成为我 们协会成员了。

我们有两种会员制,普通会员 (regular member) 和 临时会员 (associate member)。 普通会员又分终生会员 (lifetime membership) 以及年度会员,前者会费 \$500,后者会 费每两年\$100。临时会员暂不收费,但以后可能会有所改变。

目前我们还是半自动化注册 (即有部分是手工)。请到我们网站 acacr.org 在 "memership" 栏下载注册表,填好后电邮给表最后的邮件地址。

#### 我们共有三种付会员费的方式:

1. 在我们网站上用Paypal或信用产卡付。tacacr@outlook.com

2. 银行直接转帐. Routing No: 044000037, Account No: 121901257.

3. 支票. 请写明付给"Association of Chinese Americans in Cancer Research, Inc." 需要邮寄支票的, 请与shuli 联系, xia@kennedykrieger.org. 请在电邮上注明 ACACR member.

我们将在收到付款后五-七个工作日发出收据。

### 协会会员的益处:

(

协会普通会员和临时会员都可以参加wechat的讨论,信息交流,年会以及其他一些由ACACR组织的活动。普通会员还有以下一些额外的福利。

(1)协会内部选举和被选举权;

(2) 由ACACR 推荐去AACR 各种委员会和杂志编辑部:

(3) 在我们协会网站上招人广告栏上发广告(微信群里的帖子会很快被淹没);

4 在我们协会网站上贴一些会议通知;

5) 在我们协会每月一次的newsletter 上登广告 (非会员收费 \$20);

(。)我们协会网站和newsletter "Research Highlights" 栏目中将优先选发协会会员刚 发表的文章;

7) 今后ACACR 有小型奖励机会 (award opportunity), 将优先考虑我们的普通会员;

今后购买ACACR 赞助商的物品时可能有折扣机会。

普通会员今后可能有的福利还包括会员学术交流活动 (annual retreat), 成员互助等。

希望大家积极加入我们协会,众人拾柴火焰高,大家都来为建立"华人肿瘤研究学者之家"添砖加瓦"!

## Postdoctoral Fellow in Cornell Medical College, New York, United States

A postdoctoral fellow position is available in Dr. Nancy Du's laboratory (<u>www.nancydu.net</u>) in Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, Cornell University. The main research focus in the Du laboratory is to understand the molecular mechanisms of cancer metastasis using mouse models and to develop novel therapeutics.

The position is open to graduating PhD or MD/PhD students and current postdoctoral fellows with less than three years of postdoctoral experience. High levels of critical thinking, strong technical skills, and recent first author publications in high impact journals are required.

Candidates should have strong organizational, written, and verbal communication skills in English. They should have the ability to work both independently and as part of our research team. The position offers competitive salary and the exposure to a dynamic and vibrant scientific environment at Weill Cornell Medicine, Rockefeller University, and Memorial Sloan Kettering Cancer Center in the New York City area.

To apply, please send a cover letter with a brief summary of research experience and interests, CV, the contact for 3 references, and publications in one PDF file to

Yi-Chieh Nancy Du, Ph.D. Assistant Professor Department of Pathology and Laboratory Medicine Weill Cornell Medical College 1300 York Avenue, Box 69 New York, NY 10065 email: nad2012@med.cornell.edu





# Position in Molecular Mechanisms of Colon Cancer

The University of Nebraska Medical Center Eppley Institute for Research in Cancer, and the NCI-designated Fred & Pamela Buffett Cancer Center seek candidates for Postdoctoral Research Associates. Eppley Institute consists of 30 tenured/tenure-track faculty members and Buffett Cancer Center has over 100 primary members pursuing all aspects of cancer research.

The available Postdoctoral Position in Dr. Jing Wang's laboratory (https://www.unmc.edu/eppley/about/faculty/wang.html) is to study molecular mechanisms of colon cancer metastasis and drug resistance and to identify and validate novel targets associated with cell survival, invasion, angiogenesis and metastasis using cell culture and mouse models. The goal is to develop effective therapies to treat advanced colon cancer patients. Expertise in cell culture and mouse models is required and experience with immunology or bioinformatics is preferred.

The ideal candidate should have a recent Ph.D (or doctoral equivalent) degree in Biochemistry, Molecular Biology, Cell Biology, Genetics or related area with a track record of publication in peer-reviewed journals.

Applicants can send curriculum vitae, and description of research accomplishments to jjwang@unmc.edu.



President Shi-Yuan Cheng President-elect Zhenkun Lou

**Board of Directors** 

Hua Luo, Wei Gu, Jinsong Liu, Shaomeng Wang

General Secretary Shuli Xia Treasurer Yong Li

## **Committee chair/co-chair**

Advisory: Yibin Kang Annual meeting: Tongchuan He; Gloria Su; Binhua Zhou Audit: Zhaohui Feng Fundraising: Xin Fan IT-support: Wenwei Hu; Mushui Dai Membership: Yaguang Xi Public relationship: Lin Zhang



# Bronze/Event Sponsor **NOVOPTOTEIN** The ultimate protein choice

欢迎企业赞助 Please sponsor ACACR!